ASpirin and Plavix Following Coronary Artery Bypass Grafting (ASAP-CABG): A Randomized, Double-Blind, Placebo-Controlled Pilot Trial.

Slim, Ahmad M.; Fentanes, Emilio; Thomas, Dustin M.; Slim, Jennifer N.; Triana, Taylor; Ahmadian, Homayoun R.; McDonough, Ryan J.; Saucedo, Jason; Suarez, Norma J.; Pearce-Moore, Dorette; Kirchner, H. Lester; Hulten, Edward; Cury, Ricardo C.; Branch, Kelley.
Br J Med Med Res ; 2016; 14(3): 1-10
Artículo en Inglés | IMSEAR | ID: sea-182757

Documentos relacionados

  1. Secondary prevention after coronary artery bypass grafting: Anticoagulation and antiplatelet therapy is only one factor.
  2. Rationale and design for the randomized placebo-controlled double-blind trial studying the effect of single antiplatelet therapy (clopidogrel) versus dual antiplatelet therapy (clopidogrel/acetylsalicylic acid) on the occurrence of atherothrombotic events following lower extremity peripheral transluminal angioplasty (CLEAR-PATH).
  3. Dual Antiplatelet Treatment up to 72 Hours after Ischemic Stroke.
  4. Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials.
  5. Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis.
  6. Effects of cigarette smoking on older chinese men treated with clopidogrel monotherapy or aspirin monotherapy: a prospective study.
  7. Ticagrelor-Aspirin Versus Clopidogrel-Aspirin Among <i>CYP2C19</i> Loss-of-Function Carriers With Minor Stroke or Transient Ischemic Attack in Relation to Renal Function: A Post Hoc Analysis of the CHANCE-2 Trial.
  8. Antithrombotic strategies for preventing graft failure in coronary artery bypass graft.
  9. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
  10. Continuation versus discontinuation of antiplatelet therapy for bleeding and ischaemic events in adults undergoing non-cardiac surgery.